EagleClaw Cuts Sanofi Stake 60.6% as Rivals Buy the Dip

EagleClaw Capital Management LLC cut its Sanofi (NASDAQ:SNY) holdings by 60.6% in the third quarter, selling 27,535 shares and leaving 17,875 shares worth $737,000, according to its most recent Form 13F filing with the Securities and Exchange Commission. One seller. Several buyers. The divergence frames the quarter's institutional positioning in the French drugmaker.

What did other institutional investors do?

While EagleClaw stepped back, a cluster of firms moved the other way between July and September:

• Moors & Cabot Inc. raised its position by 4.4%, buying 446 shares to reach 10,497 shares valued at $433,000.
• Allworth Financial LP boosted its stake by 4.7%, adding 433 shares to hold 9,666 shares worth $412,000.
• Fifth Third Bancorp increased its position by 28.3%, purchasing 6,072 shares to own 27,533 shares worth $1,135,000.
• Ritholtz Wealth Management grew its stake by 48.3%, buying 14,880 shares to reach 45,685 shares worth $1,884,000.
• Jefferies Financial Group Inc. opened a new position worth $3,715,000.

Institutional investors and hedge funds now own 14.03% of the stock, the filings show. The message from the 13F trail: smaller allocators leaned in even as one fund exited most of its exposure.

How do analysts see the stock?

Research desks have recalibrated their views across the autumn. Wolfe Research launched coverage on Friday, October 9, with a "peer perform" rating. Wall Street Zen upgraded the shares from "hold" to "buy" on Saturday, November 7. Deutsche Bank reiterated a "buy" on Tuesday, September 29. BNP Paribas Exane lifted the stock from "neutral" to "outperform" and set a $57.00 target price on Monday. UBS Group restated a "neutral" rating on Thursday, September 17.

The aggregate picture is cautious. One analyst rates Sanofi Strong Buy, eight assign Buy and twelve assign Hold. MarketBeat data show a consensus rating of "Hold" with an average price target of $53.00.

What do the numbers say about the business?

Sanofi opened at $48.37 on Friday. The stock trades above both its 50-day moving average of $42.68 and its 200-day moving average of $44.38. Over the past year it has ranged from a low of $39.07 to a high of $52.67.

The balance sheet carries modest leverage and ample liquidity:

• Debt-to-equity ratio: 0.20
• Current ratio: 1.12
• Quick ratio: 0.27
• Market capitalization: $117.27 billion
• Price-to-earnings ratio: 23.95
• Price-to-earnings-growth ratio: 1.33
• Beta: 0.31

How did the latest quarter perform?

The company reported quarterly results on Friday, October 30, and the beat was wide. Sanofi posted earnings per share of $2.04 against a consensus estimate of $1.56, a $0.48 surplus. Revenue reached $17.25 billion versus analyst expectations of $14.30 billion. Revenue climbed 16.2% year over year, though EPS fell from $2.91 in the same quarter last year. The company recorded a return on equity of 15.16% and a net margin of 8.70%. Research analysts expect Sanofi to post 5.07 EPS for the current fiscal year. Top-line growth outpaced the prior year; the bottom line did not.

What sits behind the ticker?

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its portfolio spans immunology, oncology, rare diseases and neurology, alongside preventive vaccines for diseases such as influenza and meningitis. Dupixent, the immunology medicine developed with Regeneron, anchors the drug lineup. The company traces its origins to a French firm established in 1973 and serves patients and healthcare providers in markets around the world.

The takeaway for finance desks: a 60.6% hedge fund trim has not stopped a broad institutional tilt toward Sanofi, and a $2.9 billion revenue beat gives the buyers a number to stand on.